NV-AQARA
Aqara, a leading provider of smart home products, is thrilled to announce its participation in CES 2024. At the event, Aqara will showcase its latest innovations, including the new Border Router Plug and Smart Lock U300, as well as other advanced smart home solutions and prototypes at its booth in the Venetian Expo (#53513).
Aqara is an early advocate of the industry-unifying Matter standard and is committed to delivering seamless smart home experiences for users. The Border Router Plug and Smart Lock U300 will be Thread-capable, which will add to Aqara's growing number of native Matter products, making Aqara devices more interoperable. These two new products previewed at CES are expected to become available for order in the coming months.
Border Router Plug
The Aqara Border Router Plug represents an innovative advancement in smart plug and is among the first smart plugs announced to incorporate Thread Border Router capabilities. Equipped with Thread and dual-band Wi-Fi, this plug enables Matter controllers without Thread capability to manage Thread devices, allowing seamless integration of Thread devices into smart home systems without needing a new Matter controller.
This plug is energy-efficient, particularly in Thread-only mode, which reduces idle consumption while extending the mesh Thread network by routing the data packets. It is also energy-conscious, providing real-time and historical data on home energy consumption, enabling users to automate their electrical devices to reduce energy waste. Additionally, the Border Router Plug can sense the on/off status of the connected appliance and trigger Aqara Home automations accordingly. For example, users can have the curtains close automatically when the TV is on to eliminate potential sun glare.
The Aqara Border Router Plug utilizes an NXP® Semiconductors' secure wireless MCU. As part of the ongoing collaboration between Aqara and NXP Semiconductors, the Border Router Plug will also be featured in NXP's Smart Home Experience showcase during CES 2024, along with the NXP-powered Aqara Door and Window Sensor P2.
Smart Lock U300
The Aqara Smart Lock U300 is one of the first smart lever locks announced to feature Matter and Thread compatibility, and offers unprecedented interoperability with various smart home platforms. This versatility is coupled with an extended battery life of up to 8 months and enhanced local control, which improves responsiveness, privacy and security.
Designed for both indoor and outdoor use, the U300 replaces the traditional US lever or knob on single-bore doors and is ideal for including side entries, garage entries, home offices, basements and storage rooms. It enables a key-free lifestyle with multiple access options, including fingerprints, PIN codes, NFC, or voice assistants. Homeowners can control the lock remotely, grant temporary access to guests, and receive real-time notifications of who comes and goes - all from a smartphone.
Aqara Home App Update
At CES 2024, Aqara will also showcase Home Copilot, the new chatbot interface for the Aqara Home app, which is powered by Gen-AI. Home Copilot is designed to enhance user experiences by utilizing ambient intelligence, which helps convert real-time data and insights into actions. Ultimately, Home Copilot will be able to analyze the usage patterns in an Aqara home and proactively suggest customized automations. It will also understand natural language and configure automations per user requests. Users can automate their homes via simple voice and text instructions, which makes smart home even more intuitive and easy to use.
Initially, Home Copilot will enable Aqara Insights, a daily, weekly and monthly smart home reports for users, and provide tailored plans for energy-saving automation. It will support natural language queries for Aqara devices and automations and offer proactive assistance with device setup and troubleshooting. Home Copilot will also spearhead the AI-powered customer support interface for Aqara users in over 10 languages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108777203/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom